MK-6598

MK-6598 is an investigational, orally administered small molecule developed by Merck Sharp & Dohme (MSD) as a potent and selective inhibitor of Interleukin-4-Induced Gene 1 (IL4I1). IL4I1 is an enzyme secreted within the tumor microenvironment that contributes to immune suppression by generating hydrogen peroxide, which is cytotoxic to T cells. By inhibiting IL4I1, MK-6598 aims to reverse this immunosuppression and enhance anti-tumor immune responses. Preclinical studies demonstrated high potency against IL4I1 and established pharmacodynamic effects based on reduction of tumor phenylpyruvate in mouse models. In clinical trials, MK-6598 has been evaluated both as monotherapy and in combination with pembrolizumab for advanced or metastatic solid tumors[4][5]. The drug has shown dose-proportional pharmacokinetics, robust target engagement (as measured by phenylpyruvate reduction), and a favorable safety profile as monotherapy; some dose-limiting toxicities were observed in combination therapy[4].